<code id='DD7B605D9E'></code><style id='DD7B605D9E'></style>
    • <acronym id='DD7B605D9E'></acronym>
      <center id='DD7B605D9E'><center id='DD7B605D9E'><tfoot id='DD7B605D9E'></tfoot></center><abbr id='DD7B605D9E'><dir id='DD7B605D9E'><tfoot id='DD7B605D9E'></tfoot><noframes id='DD7B605D9E'>

    • <optgroup id='DD7B605D9E'><strike id='DD7B605D9E'><sup id='DD7B605D9E'></sup></strike><code id='DD7B605D9E'></code></optgroup>
        1. <b id='DD7B605D9E'><label id='DD7B605D9E'><select id='DD7B605D9E'><dt id='DD7B605D9E'><span id='DD7B605D9E'></span></dt></select></label></b><u id='DD7B605D9E'></u>
          <i id='DD7B605D9E'><strike id='DD7B605D9E'><tt id='DD7B605D9E'><pre id='DD7B605D9E'></pre></tt></strike></i>

          hotspot

          hotspot

          author:knowledge    Page View:24
          Fatty Liver
          Adobe

          Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

          While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

          advertisement

          “These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          Was Amgen transparent enough on FDA's concern on cancer drug?
          Was Amgen transparent enough on FDA's concern on cancer drug?

          MarkJ.Terrill/APAmidthestunningrebukeAmgensufferedatthehandsoftheU.S.FoodandDrugAdministrationthiswe

          read more
          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more

          Chan Zuckerberg Biohub Chicago to focus on inflammation

          PriscillaChan,left,withShanaKelleyandGov.J.B.PritzkerofIllinoisatthenewCZBiohubChicago.CourtesyDaleR